The US FDA has granted marketing authorization to the PMD-200 monitor developed by Israel’s Medasense Biometrics (see here previously). The device monitors pain in non-communicating (e.g., anaesthetized) patients and already has made an impact in multiple countries.

https://www.calcalistech.com/ctechnews/article/hyfvzhsrs